ALK genetic alterations drive various malignancies through aberrant tyrosine kinase activation, promoting oncogenic cell growth and survival. Here, Voena et al. outline recent advances in ALK oncogenic signalling, mechanisms of resistance, and both existing and promising new modalities to treat ALK-driven tumours.
- Claudia Voena
- Chiara Ambrogio
- Roberto Chiarle